CHMP's November Recommendations Include Suliqua, Vemlidy And Afstyla
Executive Summary
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) meets monthly to review applications for EU marketing authorizations.
You may also be interested in...
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Amgen and Allergan have filed an EU marketing authorization application for their biosimilar version of Roche’s monoclonal antibody product for cancer, Avastin (bevacizumab). In doing so, they join a growing number of biosimilars awaiting approval by the European authorities.
Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.